Ana Osa

Ana Osa

Auto-generated profile, based on publicly available information

Ana Osa


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 1998 in Circulation
Verified
Journal Article
Closed access
PDF file
JVJuana Valles
Juana Valles
MSM. Teresa Santos
M. Teresa Santos
JAJusto Aznar
Justo Aznar
AOAna Osa
Ana Osa
ALAida Lago
Aida Lago
AMAaron J. Marcus
Aaron J. Marcus
Background —Aspirin (acetylsalicylic acid, ASA) is widely used for secondary prevention of ischemic vascular events, although its protection only occurs in 25% of patients. We previously demonstrated that platelet reactivity is enhanced by a prothrombotic effect of erythrocytes in a thromboxane-independent manner. This diminishes the antithrombotic therapeutic potential of ASA. Recent data from our laboratory indicate that the prothrombotic effect of erythrocytes also contains an ASA-sensitive component. In accordance with this observation, intermittent treatment with high-dose ASA reduced the prothrombotic effects of erythrocytes ex vivo in healthy volunteers. In the present study, the effects of platelet-erythrocyte interactions were evaluated ex vivo in 82 patients with vascular disease: 62 patients with ischemic heart disease treated with 200 mg ASA/d and 20 patients with ischemic stroke treated with 300 mg ASA/d. Methods and Results —Platelet activation (release reaction) and platelet recruitment (fluid-phase proaggregatory activity of cell-free releasates from activated platelets) were assessed after collagen stimulation (1 μg/mL) of platelets, platelet-erythrocyte mixtures, or whole blood. Platelet thromboxane A 2 synthesis was inhibited by >94% by ASA administration in all patients. Importantly, platelet recruitment followed one of three distinct patterns. In group A (n=32; 39%), platelet recruitment was blocked by ASA both in the presence and absence of erythrocytes. In group B (n=37; 45%), recruitment was abolished when platelets were evaluated alone but continued in the presence of erythrocytes, indicating a suboptimal effect of ASA on erythrocytes of this patient group. In group C (n=13; 16%), detectable recruitment in stimulated platelets alone persisted and was markedly enhanced by the presence of erythrocytes. Conclusions —In two thirds of a group of patients with vascular disease, 200 to 300 mg ASA was insufficient to block platelet reactivity in the presence of erythrocytes despite abolishing thromboxane A 2 synthesis. Platelet activation in the presence of erythrocytes can induce the release reaction and generate biologically active products that recruit additional platelets into a developing thrombus. Insufficient blockade of this proaggregatory property of erythrocytes can lead to development of additional ischemic complications.

3 September 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
EZEsther Zorio
Esther Zorio
RCRemedios Castelló
Remedios Castelló
CFCristina Falcó
Cristina Falcó
FEFrancisco España
Francisco España
AOAna Osa
Ana Osa
AEAmparo Estellés
Amparo Estellés
Summary. Thrombin‐activatable fibrinolysis inhibitor (TAFI) is a fibrinolytic inhibitor. Studies in coronary artery disease have reported increased TAFI activity (TAFI Act) and low TAFI antigen (TAFI Ag) levels. This controversy might be explained by the polymorphisms of its gene. Only the Thr325Ile polymorphism modulates both TAFI Ag and Act levels in vitro. This study assessed TAFI Ag and Act levels, TAFI Thr325Ile polymorphism, the fibrinolytic and protein C systems and some prothrombotic mutations in a young patient group (n = 127, aged < 51 years, with myocardial infarction) and a control group (n = 99) with similar characteristics. Patients exhibited hypofibrinolysis and higher plasminogen activator inhibitor‐1 (PAI‐1) levels. Although TAFI Ag was lower, TAFI Act level was significantly higher in patients and positively correlated with PAI‐1, protein C inhibitor and the euglobulin lysis time. No differences between groups were found according to the Thr325Ile polymorphism. Irrespective of the genotype, patients had higher TAFI Act levels. The Ile‐325 variant exhibited lower TAFI Ag levels. We suggest that the hypofibrinolysis observed in these patients results from an increase in both PAI‐1 and TAFI Act, which is not related to the Thr325Ile polymorphism. Patients have high TAFI Act with low TAFI Ag levels, probably because of an increased stability of TAFI related to a fibrinolytic hypofunction.

21 June 2012 in ISRN Cardiology
Verified
Journal Article
Open access
PDF file
FBF. Buendía-Fuentes
F. Buendía-Fuentes
MAM. A. Arnau-Vives
M. A. Arnau-Vives
AAAntonio Arnau
Antonio Arnau
YJY. Jiménez-Jiménez
Y. Jiménez-Jiménez
JRJ. Rueda-Soriano
J. Rueda-Soriano
MPM. A. Palencia-Pérez
M. A. Palencia-Pérez
Introduction. Artifactual variations in the ST segment may lead to confusion with acute coronary syndromes. Objective. To evaluate how the technical characteristics of the recording mode may distort the ST segment. Material and Method. We made a series of electrocardiograms using different filter configurations in 45 asymptomatic patients. A spectral analysis of the electrocardiograms was made by discrete Fourier transforms, and an accurate recomposition of the ECG signal was obtained from the addition of successive harmonics. Digital high-pass filters of 0.05 and 0.5 Hz were used, and the resulting shapes were compared with the originals. Results. In 42 patients (93%) clinically significant alterations in ST segment level were detected. These changes were only seen in “real time mode” with high-pass filter of 0.5 Hz. Conclusions. Interpretation of the ST segment in “real time mode” should only be carried out using high-pass filters of 0.05 Hz.

1 July 2004 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MAMiguel A. Arnau-Vives
Miguel A. Arnau-Vives
LALuis Almenar
Luis Almenar
IHIsabel Hervas
Isabel Hervas
AOAna Osa
Ana Osa
LDLuis Martinez Dolz
Luis Martinez Dolz
MPMiguel Palencia
Miguel Palencia

1 November 2005 in Transplantation Proceedings
Verified
Journal Article
Closed access
LDLuis Martinez Dolz
Luis Martinez Dolz
LAL. Almenar
L. Almenar
LML. Martı́nez-Ortiz
L. Martı́nez-Ortiz
MAM.A. Arnau
M.A. Arnau
CCC. Chamorro
C. Chamorro
MPM. Palencia
M. Palencia

1 January 2002 in Revista Espanola de Cardiologia
Verified
Journal Article
Closed access
JOJoaquín Osca
Joaquín Osca
AQAnastasio Quesada
Anastasio Quesada
MAMiguel A. Arnau
Miguel A. Arnau
AOAna Osa
Ana Osa
LALuis Almenar
Luis Almenar
AMAntonio Mateo
Antonio Mateo